We are also happy to advise you personally
Focus on biotechnology - making medical history together
Private venture investment “Life Science” – Pharmacology
Our special AIF investment company, Görlich GmbH & Co. 1st BioTech KG, has invested in 4TEEN4 Pharmaceuticals GmbH as lead investor in financing round C, currently with EUR 10 million. Initially, a further EUR 10 million is to be subscribed by the end of 2024.
Investors in our BioTech fund have the opportunity to invest in pioneering innovations in medicine.
The target company of our BioTech investment fund, 4TEEN4 Pharmaceuticals GmbH (HRB 10555 NP), was founded in 2013 and is exclusively pursuing the development of a biomarker to detect a disease leading to shock (and death) (diagnostics of the DPP3 enzyme) and an antibody to cure it. These 4TEEN4 products have the potential to become revolutionary blockbusters on the global medical market.
The Görlich GmbH & Co. 1. BioTech KG is an authorized investor and has already subscribed € 10 million, with a pre-money valuation of € 100 million. Our Beteiligungs-KG offers semi-professional investors the opportunity to invest from 200,000 euros.
The investment amount of the respective investors will be passed on in full to 4TEEN4. The ongoing costs of the KG, in particular for the requirements of the Federal Financial Supervisory Authority and the ongoing business, are financed from the contributions of the personally liable general partner (Dr. Görlich GmbH International). The initial contribution of EUR 100,000 has already been paid in by the general partner and can be increased by the general partner if required. There are no additional funding obligations for investors.
After the successful commercialization of 4TEEN4 and its patents, the investors will receive all returns on their investment in full up to a doubling of their initial investment. Any returns exceeding this threshold will be split with 80% going to the investor and 20% going to the founding shareholders of the KG as remuneration.
Should we have caught your interest, please do not hesitate to contact us directly.
Görlich & Co. 1. BioTech KG (BaFin ID 70171144)
Fund type
Domestic closed-end special AIF (alternative investment fund)
Year of issue
2024
Issue capital
€ 30 million
Fondswährung
EURO
Minimum investment amount
€ 200.000
First investment
4TEEN4 Pharmaceuticals GmbH
General partner
Dr. Görlich GmbH International
Registered capital management company
GG Capital Management GmbH (BaFin ID 10163436)
Are you interested in further information?
We will be happy to advise you personally
Of course you can also reach us by phone:
BioTech-Fonds Görlich GmbH & Co. 1st BioTech KG is aimed exclusively at professional and semi-professional investors within the meaning of the German Investment Code (section 1 (19) no. 32, 33 KAGB). Among other things, a semi-professional investor undertakes to invest at least EUR 200,000 and must have the necessary expertise, experience and knowledge to make such an investment.
Please select your investor type
